Inactive Instrument

MyoKardia, Inc.

Equities

MYOK

US62857M1053

Biotechnology & Medical Research

June Lee, M.D., Executive Vice President, Chief Development Officer of Myokardia, Inc. to End on a Date No Later Than June 30, 2020

October 04, 2019 at 05:18 pm EDT

On September 30, 2019, it was agreed that June Lee, M.D., Executive Vice President, Chief Development Officer of MyoKardia, Inc., would be ending her employment with the company following a transition period, which commenced on September 30, 2019 and will end on a date no later than June 30, 2020.

Latest news about MyoKardia, Inc.

Transcript : MyoKardia, Inc., Q1 2022 Earnings Call, Apr 29, 2022	22-04-29
Transcript : MyoKardia, Inc. Presents at Barclays Global Healthcare Conference 2022, Mar-16-2022 01:35 PM	22-03-16
Bristol Myers Squibb : Posts 4Q Adjusted Profit, Growth for Eliquis, Opdivo	21-02-04	DJ
Bristol Myers sees up to $25 billion a year of new revenue from current drug pipeline	21-01-11	RE
Avidity Biosciences, Inc. Enters into A Research Collaboration with MyoKardia	21-01-08	CI
MyoKardia, Inc. Announces Board Changes	20-11-17	CI
MyoKardia, Inc.(NasdaqGS:MYOK) dropped from S&P Pharmaceuticals Select Industry Index	20-11-17	CI
MyoKardia, Inc.(NasdaqGS:MYOK) dropped from S&P Global BMI Index	20-11-17	CI
MyoKardia, Inc.(NasdaqGS:MYOK) dropped from S&P TMI Index	20-11-17	CI
MyoKardia, Inc.(NasdaqGM:MYOK) dropped from Russell 2000 Value Index	20-11-17	CI
MyoKardia, Inc.(NasdaqGM:MYOK) dropped from Russell Small Cap Comp Value Index	20-11-17	CI
MyoKardia, Inc.(NasdaqGM:MYOK) dropped from Russell 3000 Value Index	20-11-17	CI
MyoKardia, Inc.(NasdaqGM:MYOK) dropped from Russell 2500 Value Index	20-11-17	CI
MyoKardia, Inc.(NasdaqGM:MYOK) dropped from Russell 3000 Index	20-11-17	CI
MyoKardia, Inc.(NasdaqGM:MYOK) dropped from Russell 3000 Growth Index	20-11-17	CI
MyoKardia, Inc.(NasdaqGM:MYOK) dropped from Russell Small Cap Completeness Index	20-11-17	CI
MyoKardia, Inc.(NasdaqGM:MYOK) dropped from Russell 2000 Index	20-11-17	CI
MyoKardia, Inc.(NasdaqGM:MYOK) dropped from Russell 2500 Index	20-11-17	CI
MyoKardia, Inc.(NasdaqGM:MYOK) dropped from Russell 2500 Growth Index	20-11-17	CI
MyoKardia, Inc.(NasdaqGM:MYOK) dropped from Russell 2000 Growth Index	20-11-17	CI
MyoKardia, Inc.(NasdaqGM:MYOK) dropped from Russell Small Cap Comp Growth Index	20-11-17	CI
MyoKardia, Inc.(NasdaqGM:MYOK) dropped from Russell 2000 Value-Dynamic Index	20-11-17	CI
MyoKardia, Inc.(NasdaqGM:MYOK) dropped from Russell 2500 Growth-Dynamic Index	20-11-17	CI
MyoKardia, Inc.(NasdaqGM:MYOK) dropped from Russell 2500 Value-Dynamic Index	20-11-17	CI
MyoKardia, Inc.(NasdaqGM:MYOK) dropped from Russell 2500 Dynamic Index	20-11-17	CI

Chart MyoKardia, Inc.

Duration

Period

More charts

Company Profile

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	114B
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B
BIONTECH SE	-11.90%	22.41B
ARGENX SE	+0.23%	22.28B
GENMAB A/S	-5.52%	19.07B
WUXI APPTEC CO., LTD.	-37.36%	18B
BEIGENE, LTD.	-5.17%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.28B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.55B

Bio Therapeutic Drugs